Office of Health Economics

Not following anyone yet

adrian towse biotechnology and pharmaceuticals cancer england eq-5d health care health economics health technology assessment hta htai innovation ispor medicine medicines nhs nice ohe pharmaceutical industry pharmaceuticals presentation pricing proms quality of life r&d reimbursement uk more…

aai access access to care adolescents adrian towse affordability amr antibacterials antibiotics antimicrobial resistance antimicrobials approaches to value assessment asia assessment australia big data biosimilars biotechnology and pharmaceuticals brazil burden of illness cadth cancer caregiving cea children china clinical evaluation clinical trial commissioning competition cost cost effectiveness cost of r&d cost-effectiveness cost-effectiveness analysis cost-effectiveness threshold costa rica costs daas decision modelling devlin diabetic retinopathy diagnostics differential pricing direct acting antivirals discrete choice discrete choice experiment disease management drug development drugs economics economics of cures economics of r&d ed-5d elderly ema emerging markets end of life end of life medicines end-of-life end-of-life care england eq-5d eq-5d-3l eq-5d-5l eq-5d-y eq-vas europe euroqol fairness forecast framing effects france funding generics genomics germany global engagement global health healtcare decision making health care health care costs health care systems health economics health inequality health insurance health outcomes health policy health status health system capacity health technology assessment heor hepatitis c hip surgery hta htai icer incentives indication indication-based pricing inequality innovation intellectual property international comparisons international volunteering interviews ipor washing dc ispe ispor ispor summit kings fund koonal koonal shah labour productivity latin america ldcs learning outcomes long-term care lou garrison mapping market access market competition markov matching measurement for drugs medical research medicare medicine medicines mental health methodology mhra mlics nancy devlin nhs nice ohe oncology medicines open source orphan drugs outcome-based payments outcomes patient access schemes patient reported outcomes patient-reported outcomes patients pbrsa personalized medicine pharm pharmaceutical pharmaceutical industry pharmaceutical innovation pharmaceutical regulation pharmaceuticals pharmacoeconomics policy politics pprs preferences prescription drug presentation presentations price and reimbursement price discrimination prices pricing proms proms conference public public attitudes qaly qaly's qalys qualitative analysis quality quality of life r&d r&d incentives rare diseases rates of return real-world data real-world evidence reimbursement research research and development resistance revenue risk screening spillovers stated preferences static and dynamic efficiency stratified medicine supplementary patent certificates sustainability systematic review taiwan technology time trade off time trade-off transparency tto tto valuations of health states uae uhc uk unmet need uptake uptake curves us usa utilities vaccines valuation value value-based pricing vbp visual analogue scale washington dc wellbeing İçer …less